Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

por Elneil, Sohier, Lalezari, Jacob P., Pourhassan, Nader Z.
Publicado 2021

Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab

por Agresti, Nicholas, Lalezari, Jacob P., Amodeo, Phillip P., Mody, Kabir, Mosher, Steven F., Seethamraju, Harish, Kelly, Scott A., Pourhassan, Nader Z., Sudduth, C. David, Bovinet, Christopher, ElSharkawi, Ahmed E., Patterson, Bruce K., Stephen, Reejis, Sacha, Jonah B., Wu, Helen L., Gross, Seth A., Dhody, Kush
Publicado 2021

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

por Nelson, David R, Cooper, James N, Lalezari, Jacob P, Lawitz, Eric, Pockros, Paul J, Gitlin, Norman, Freilich, Bradley F, Younes, Ziad H, Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J, Ortiz-Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M, Varunok, Peter, Kowdley, Kris V, Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A
Publicado 2015

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

por Eron, Joseph J., Clotet, Bonaventura, Durant, Jacques, Katlama, Christine, Kumar, Princy, Lazzarin, Adriano, Poizot-Martin, Isabelle, Richmond, Gary, Soriano, Vincent, Ait-Khaled, Mounir, Fujiwara, Tamio, Huang, Jenny, Min, Sherene, Vavro, Cindy, Yeo, Jane, Walmsley, Sharon L., Cox, Joseph, Reynes, Jacques, Morlat, Philippe, Vittecoq, Daniel, Livrozet, Jean-Michel, Fernández, Pompeyo Viciana, Gatell, Jose M., DeJesus, Edwin, DeVente, Jerome, Lalezari, Jacob P., McCurdy, Lewis H., Sloan, Louis A., Young, Benjamin, LaMarca, Anthony, Hawkins, Trevor
Publicado 2013

Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species

por Chang, Xiao L., Reed, Jason S., Webb, Gabriela M., Wu, Helen L., Le, Jimmy, Bateman, Katherine B., Greene, Justin M., Pessoa, Cleiton, Waytashek, Courtney, Weber, Whitney C., Hwang, Joseph, Fischer, Miranda, Moats, Cassandra, Shiel, Oriene, Bochart, Rachele M., Crank, Hugh, Siess, Don, Giobbi, Travis, Torgerson, Jeffrey, Agnor, Rebecca, Gao, Lina, Dhody, Kush, Lalezari, Jacob P., Bandar, Ivo Sah, Carnate, Alnor M., Pang, Alina S., Corley, Michael J., Kelly, Scott, Pourhassan, Nader, Smedley, Jeremy, Bimber, Benjamin N., Hansen, Scott G., Ndhlovu, Lishomwa C., Sacha, Jonah B.
Publicado 2022